March 3, 2026
UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
Pharmaceuticals, Biotechnology and Life Sciences
Tag: UroGen
September 24, 2019
UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer
UGN-101: Consistent Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Durability…